What is TEVA's forecasted revenue?

Teva Pharmaceutical Industries Limited is forecasted to generate $18.9B in next-four-quarter revenue, representing +9.4% year-over-year growth.

How accurate is the TEVA revenue forecast model?

The model has 4.8% training MAPE (Mean Absolute Percentage Error). In a holdout test, it predicted $4.5B versus the actual $4.1B.

Teva Pharmaceutical Industries Limited TEVA

Revenue Intelligence Report • 74 quarters of SEC filing data • Updated 2026-10-14 • Data through 2026-06-30

Teva Pharmaceutical Industries Limited's latest quarterly revenue is $4.1B for the period ending 2026-06-30. The model projects $18.9B across the next four quarters (+9.4% versus the preceding four quarters). The forecast uses SG&A data; model selection and estimation exclude the latest quarter, whose retrospective holdout error is 7.9%. These are statistical associations, not estimates of the causal effect of spending.

Investment Thesis

The GAM forecast is based on reported revenue and SG&A data through 2026-06-30. Training MAPE measures fit to historical data; the separately reported holdout error measures a withheld quarter. Spending coefficients describe associations and do not establish causation.

Next 4 Quarters

$18.9B

+9.4% YoY

SG&A Multiplier

$3.28 per $1

Training Fit

4.8% MAPE

Retrospective holdout (Q2 FY2026): The model predicted $4.47B vs the actual $4.14B — an error of 7.9%.
Retrospective one-quarter holdout: model fitting and selection exclude this quarter. Historical inputs use the latest available restatements, so this is not a preserved real-time forecast.

Note: Teva Pharmaceutical Industries Limited does not report R&D expenses separately. The model uses the available expense measure without a separate R&D term.

Revenue Forecast

Quarterly Detail

Quarter	Model Forecast	Actual	95% Range	YoY Growth	Status
Q2 FY2026 Period end 2026-06-30	$4.47B	$4.14B	$3.81B–$5.24B	+7.0%	✓ In range
Q3 FY2026 Period end 2026-09-30	$4.52B		$3.84B–$5.31B	+0.8%
Q4 FY2026 Period end 2026-12-31	$5.05B		$4.21B–$6.06B	+7.2%
Q1 FY2027 Period end 2027-03-31	$4.61B		$3.90B–$5.45B	+15.8%
Q2 FY2027 Period end 2027-06-30	$4.76B		$4.00B–$5.66B	+14.9%

Seasonal Factors

Multiplicative seasonal adjustment: These factors capture Teva Pharmaceutical Industries Limited's systematic quarterly revenue patterns relative to the trend model. A factor of 1.05 means that quarter typically runs 5% above the underlying trend; 0.95 means 5% below. Factors are computed as the median of (actual / fitted) across all available quarters.

Fiscal Quarter	Seasonal Factor	vs Trend	Interpretation	Obs.
FQ1 (Jan–Mar)	0.9663	-3.4%	-3.4% below trend	19
FQ2 (Apr–Jun)	0.9895	-1.0%	In line with trend	18
FQ3 (Jul–Sep)	1.0129	+1.3%	In line with trend	18
FQ4 (Oct–Dec)	1.0049	+0.5%	In line with trend	18

Spending and Revenue

Reading this chart: Each line shows the cumulative revenue association per $1 of spending over subsequent quarters. These estimates describe historical associations and do not establish causation.

Time-Varying Spending Associations

Time-varying analysis: A penalized spline model (GAM) tracks the association between log spending and log revenue over 74 quarters. Its coefficients describe conditional historical associations, not causal returns on spending.
Current SG&A elasticity: 0.7995x
The model-term chart shows relative absolute term magnitudes. Its percentages are not shares of revenue or causal contributions to growth.

Enhanced forecast: The time-varying model (GAM) was selected using training fit, before evaluating the withheld quarter. Its holdout error is 7.9%.

Want this analysis for your portfolio?

I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.

Get in Touch